Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.

PRMT5 plays important roles in diverse cellular processes and is upregulated in several human malignancies. Besides, PRMT5 has been validated as an anticancer target in mantle cell lymphoma. In this study, we found a potent and selective PRMT5 inhibitor by performing structure-based virtual screening and hit optimization. The identified compound 17 (IC50 = 0.33 μM) exhibited a broad selectivity against a panel of other methyltransferases. The direct binding of 17 to PRMT5 was validated by surface plasmon resonance experiments, with a Kd of 0.987 μM. Kinetic experiments indicated that 17 was a SAM competitive inhibitor other than the substrate. In addition, 17 showed selective antiproliferative effects against MV4-11 cells, and further studies indicated that the mechanism of cellular antitumor activity was due to the inhibition of PRMT5 mediated SmD3 methylation. 17 may represent a promising lead compound to understand more about PRMT5 and potentially assist the development of treatments for leukemia indications.

[1]  Nikos Koundouros,et al.  Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer , 2018, Front. Oncol..

[2]  Z. Chen,et al.  Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide. , 2016, Organic & biomolecular chemistry.

[3]  Cheng Luo,et al.  Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer. , 2016, Cancer cell.

[4]  Xiaomin Luo,et al.  Discovery of Novel Inhibitors Targeting the Menin-Mixed Lineage Leukemia Interface Using Pharmacophore- and Docking-Based Virtual Screening , 2016, J. Chem. Inf. Model..

[5]  C. Luo,et al.  Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation. , 2016, Journal of medicinal chemistry.

[6]  Jin Zhang,et al.  Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays , 2016, J. Chem. Inf. Model..

[7]  Cheng Luo,et al.  Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation. , 2015, Nature chemistry.

[8]  Hualiang Jiang,et al.  Discovery and Optimization of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Pharmacophore- and Docking-Based Virtual Screening. , 2015, Journal of medicinal chemistry.

[9]  Robert A Copeland,et al.  A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. , 2015, Nature chemical biology.

[10]  Claudio Agostinelli,et al.  Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. , 2015, Blood.

[11]  Cheng Luo,et al.  Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2. , 2014, Journal of medicinal chemistry.

[12]  Hualiang Jiang,et al.  Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening. , 2014, Journal of medicinal chemistry.

[13]  Cheng Luo,et al.  Antiinfective therapy with a small molecule inhibitor of Staphylococcus aureus sortase , 2014, Proceedings of the National Academy of Sciences.

[14]  Guido Marcucci,et al.  Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. , 2014, Cancer research.

[15]  Claudio Agostinelli,et al.  Protein Arginine Methyltransferase 5 (PRMT5) Inhibition Induces Lymphoma Cell Death through Reactivation of the Retinoblastoma Tumor Suppressor Pathway and Polycomb Repressor Complex 2 (PRC2) Silencing* , 2013, The Journal of Biological Chemistry.

[16]  D. Joshi,et al.  Synthesis and evaluation of novel benzimidazole derivatives as antimicrobial agents , 2013, Medicinal Chemistry Research.

[17]  J. Balzarini,et al.  Chemo-Enzymatic Synthesis and Biological Evaluation of 5,6-Disubstituted Benzimidazole Ribo- and 2′-Deoxyribonucleosides , 2012 .

[18]  Aiping Zhang,et al.  Crystal structure of the human PRMT5:MEP50 complex , 2012, Proceedings of the National Academy of Sciences.

[19]  Li-Jen Su,et al.  Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin‐dependent kinases and the phosphoinositide 3‐kinase/AKT signaling cascade , 2012, Cancer science.

[20]  Cheng Luo,et al.  Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. , 2012, Organic & biomolecular chemistry.

[21]  D. Kerr,et al.  Arginine methylation controls growth regulation by E2F‐1 , 2012, The EMBO journal.

[22]  Troy E. Sandberg,et al.  Human Protein Arginine Methyltransferase 7 (PRMT7) Is a Type III Enzyme Forming ω-NG-Monomethylated Arginine Residues* , 2012, The Journal of Biological Chemistry.

[23]  Yu-Jie Hu,et al.  Versatility of PRMT5-induced methylation in growth control and development. , 2011, Trends in biochemical sciences.

[24]  Jian Jin,et al.  Targets in Epigenetics: Inhibiting the Methyl Writers of the Histone Code , 2011, Current chemical genomics.

[25]  Matthew A Powers,et al.  Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. , 2011, Cancer research.

[26]  S. Wolf.  The protein arginine methyltransferase family: an update about function, new perspectives and the physiological role in humans , 2009, Cellular and Molecular Life Sciences.

[27]  Frank Herrmann,et al.  Human protein arginine methyltransferases in vivo – distinct properties of eight canonical members of the PRMT family , 2009, Journal of Cell Science.

[28]  S. Clarke,et al.  Protein arginine methylation in mammals: who, what, and why. , 2009, Molecular cell.

[29]  Sharmistha Pal,et al.  Protein Arginine Methyltransferase 5 Suppresses the Transcription of the RB Family of Tumor Suppressors in Leukemia and Lymphoma Cells , 2008, Molecular and Cellular Biology.

[30]  Graydon B. Gonsalvez,et al.  Two distinct arginine methyltransferases are required for biogenesis of Sm-class ribonucleoproteins , 2007, The Journal of cell biology.

[31]  Sharmistha Pal,et al.  Low levels of miR‐92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma , 2007, The EMBO journal.

[32]  Cyrus Martin,et al.  The diverse functions of histone lysine methylation , 2005, Nature Reviews Molecular Cell Biology.

[33]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[34]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[35]  G. Meister,et al.  Methylation of Sm proteins by a complex containing PRMT5 and the putative U snRNP assembly factor pICln , 2001, Current Biology.

[36]  Juri Rappsilber,et al.  The Methylosome, a 20S Complex Containing JBP1 and pICln, Produces Dimethylarginine-Modified Sm Proteins , 2001, Molecular and Cellular Biology.

[37]  R T Borchardt,et al.  Sinefungin, a potent inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viral multiplication. , 1978, The Journal of biological chemistry.